Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia

Cancer

Volumn 119, Issue 12, 2013, Pages 2258-2267

  Hopfinger, Georg ^a   Busch, Raymonde ^b   Pflug, Natali ^c   Weit, Nicole ^c   Westermann, Anne ^c   Fink, Anna Maria ^c   Cramer, Paula ^c   Reinart, Nina ^c   Winkler, Dirk ^d   Fingerle Rowson, Günter ^c   Stilgenbauer, Stephan ^d   Döhner, Hartmut ^d   Kandler, Gabriele ^a   Eichhorst, Barbara ^c   Hallek, Michael ^c   Herling, Marco ^c  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

alemtuzumab, fludarabine, mitoxantrone, and cyclophosphamide chemotherapy; mature T cell leukemia lymphoma; T cell leukemia 1; T cell prolymphocytic leukemia

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; GANCICLOVIR; IMMUNOGLOBULIN G ANTIBODY; MITOXANTRONE; ONCOPROTEIN; PROTEIN TCL1; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLEEDING DISORDER; BLOOD TOXICITY; CARDIOTOXICITY; CHILL; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HEART ARREST; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; ISCHEMIC HEART DISEASE; LEUKEMIA REMISSION; LEUKOPENIA; LIMB ISCHEMIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; ORAL MUCOSITIS; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROLYMPHOCYTIC LEUKEMIA; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SKIN MANIFESTATION; SKIN TOXICITY; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERTIGO; VIRUS REACTIVATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, PROLYMPHOCYTIC, T-CELL; MALE; MIDDLE AGED; MITOXANTRONE; PROTO-ONCOGENE PROTEINS; REMISSION INDUCTION; TREATMENT OUTCOME; VIDARABINE;

EID: 84878573270     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27972     Document Type: Article

References (30)

1. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991; 78: 3269-3274.
2. Soulier J, Pierron G, Vecchione D, et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2001; 31: 248-254.
3. Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D,. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004; 104: 328-335.
4. Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008; 111: 328-337.
5. Catovsky D,. Prolymphocytic leukaemia. Nouv Rev Fr Hematol. 1982; 24: 343-347.
6. Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997; 15: 2667-2672.
7. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001; 98: 1721-1726.
8. Keating MJ, Cazin B, Coutré S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002; 20: 205-213.
9. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005; 23: 7024-7031.
10. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002; 99: 2245-2247.
11. Stilgenbauer S, Zenz T, Winkler D, et al; German Chronic Lymphocytic Leukemia Study Group,. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009; 27: 3994-4001.
12. Eichhorst BF, Busch R, Hopfinger G, et al. German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006; 107: 885-891.
13. Bosch F, Ferrer A, Lõpez-Guillermo A, et al; GELCAB (Grup per l'Estudi dels Limfomes a Catalunya i Balears). Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002; 119: 976-984.
14. Hillmen P, Cohen DR, Cocks K, et al; NCRI CLL Sub-Group. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. Br J Haematol. 2011; 152: 570-578.
15. Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon, France: International Agency for Research on Cancer; 2008.
16. Gesk S, Martin-Subero JI, Harder L, et al. Molecular cytogenetic detection of chromosomal breakpoints in T-cell receptor gene loci. Leukemia. 2003; 17: 738-745.
17. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990-4997.
18. Ravandi F, O'Brien S, Jones D, et al. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2005; 6: 234-239.
19. Dohner H, Ho AD, Thaler J, et al. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J Natl Cancer Inst. 1993; 85: 658-662.
20. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D,. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol. 1994; 12: 2588-2593.
21. Maeda A, Iwai K, Ishibashi T,. Successful treatment of T-cell prolymphocytic leukemia (T-PLL) with fludarabine monophosphate [in Japanese]. Rinsho Ketsueki. 2009; 50: 658-662.
22. Ravandi F, Aribi A, O'Brien S, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009; 27: 5425-5430.
23. Dearden CE, Khot A, Else M, et al. Alemtuzumab therapy in T-cell prolymphocytic leukaemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011; 118: 5799-5802.
24. Krishnan B, Else M, Tjonnfjord GE, et al. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol. 2010; 149: 907-910.
25. Wiktor-Jedrzejczak W, Dearden C, de Wreede L, et al; EBMT Chronic Leukemia Working Party. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia. 2012; 26: 972-976.
26. O'Brien SM, Keating MJ, Mocarski ES,. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma. 2006; 7: 125-130.
27. Weidmann E, Hess G, Chow KU, et al. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma. 2010; 51: 447-455.
28. Lundin J, Kennedy B, Dearden C, Dyer MJ, Osterborg A,. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. Blood. 2005; 105: 4148-4149.
29. Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M,. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood. 2004; 104: 655-658.
30. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109: 3122-3131.